脑转移瘤多分次立体定向放疗中GTV D98%与局部控制显著相关
这项回顾性研究分析了81例未切除的大体积脑转移瘤接受基于直线加速器的多分次立体定向放疗(3次分割,GTV处方33 Gy),1年和2年局部控制率分别为79.7%和69.7%。多因素分析显示GTV D98%和腺癌组织学类型是局部控制的显著预测因素,GTV D98%≥29 Gy组1年局部控制率显著优于<29 Gy组(91.9% vs 69.6%,p=0.030)。
要点
- GTV D98%是多分次SRT治疗脑转移瘤局部控制的显著预测因素(HR=0.84,p=0.004)。
- GTV D98%≥29 Gy(BED12=52.4 Gy)组1年局部控制率91.9%,显著优于<29 Gy组的69.6%(p=0.030)。
- 建议GTV BED12 98%≥52.4-53.4 Gy以改善局部控制,对应3次分割GTV D98%≥29-29.4 Gy。
核心结论
- GTV D98%是脑转移瘤立体定向放疗局部控制的强且可重复的显著预测因素。
- 处方剂量应使GTV BED12 98%≥52.4-53.4 Gy以显著改善局部控制。
研究设计与样本
- 回顾性研究,纳入2017至2019年连续收治的81例未切除大体积脑转移瘤,接受基于直线加速器的VMAT多分次立体定向放疗(3次分割)。
- GTV处方剂量33 Gy,PTV处方剂量23.1 Gy(70%等剂量线),3次分割。
- 脑转移瘤最大径均值25.1 mm,GTV均值7.2 cc,中位随访10.2个月。
主要发现
- 1年和2年局部控制率分别为79.7%和69.7%。
- 单因素和多因素分析中,GTV D98%(HR=0.84,95%CI 0.75-0.95,p=0.004)和腺癌组织学类型(HR=0.29,95%CI 0.09-0.96,p=0.042)是局部控制的显著预测因素。
- GTV D98%≥29 Gy组1年局部控制率91.9%,<29 Gy组69.6%(p=0.030),29 Gy对应BED12=52.4 Gy。
- BED12≥53.4 Gy(对应1次分割GTV D98%≥20 Gy和3次分割GTV D98%≥29.4 Gy)时未观察到肿瘤进展。
- 中位总生存期为15个月,症状性放射性坏死发生率为4.9%。
关键数值与推荐
- GTV D98%阈值29 Gy(3次分割)与局部控制显著相关,对应BED12=52.4 Gy。
- 推荐GTV BED12 98%≥52.4-53.4 Gy,对应1次分割GTV D98%≥19.7-20 Gy和3次分割GTV D98%≥29-29.4 Gy。
临床怎么用
- 多分次立体定向放疗治疗未切除大体积脑转移瘤时,应关注GTV D98%而非仅看处方剂量。
- 计划评估时确保GTV BED12 98%达到52.4-53.4 Gy以上,以显著改善局部控制。
局限性
- 回顾性研究设计。
- 样本量81例,中位随访10.2个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic radiotherapy (SRT) should be applied with a biologically effective dose with an α/β of 12 (BED12) ≥ 40 Gy to reach a 1-year local control (LC) ≥ 70%. The aims of this retrospective study were to report a series of 81 unresected large brain metastases treated with Linac-based multifraction SRT according to the ICRU 91 and to identify predictive factors associated with LC. METHODS: Included in this study were the first 81 brain metastases (BM) consecutively treated with Linac-based volumetric modulated arc therapy (VMAT) multifraction SRT from 2017 to 2019. The prescribed dose was 33 Gy for the GTV and 23.1 Gy (70% isodose line) for the PTV in 3 fractions (3f). Mean BM largest diameter and GTV were 25.1 mm and 7.2 cc respectively. Mean follow-up was 10.2 months. RESULTS: LC was 79.7% and 69.7% at 1 and 2 years respectively. Significant predictive factors of LC were GTV D98% (HR = 0.84, CI 95% = 0.75-0.95, p = 0.004) and adenocarcinoma as the histological type (HR = 0.29, CI 95% = 0.09-0.96, p = 0.042) in univariate and multivariate analysis. A threshold of 29 Gy for GTV D98% was significantly correlated to LC (1-year LC = 91.9% for GTV D98% ≥ 29 Gy vs 69.6% for GTV D98% < 29 Gy (p = 0.030)), corresponding to a BED12 = 52.4 Gy. No tumor progression was observed for a BED12 ≥ 53.4 Gy, corresponding to a GTV D98% ≥ 20 Gy /1f and GTV D98% ≥ 29.4 Gy 3f. Median OS was 15 months. Symptomatic radionecrosis occurred in 4.9% of cases. CONCLUSION: The GTV D98% is a strong reproducible significant predictive factor of LC for brain SRT. Dose prescription should lead to a GTV BED12 98% ≥ 52.4-53.4 Gy to significantly improve LC, corresponding to respectively a GTV D98% ≥ 19.7-20 Gy/1f and 29-29.4 Gy/3f.
引用
- Dupic G, Brun L, Molnar I, et al. Significant correlation between gross tumor volume (GTV) D98% and local control in multifraction stereotactic radiotherapy (MF-SRT) for unresected brain metastases. Radiother Oncol. 2020. PMID: 33245944. doi:10.1016/j.radonc.2020.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。